4074 Background: The PI3K/Akt/mTOR pathway, a key regulator of cellular proliferation and
angiogenesis, has emerged as a contributor to hepatocarcinogenesis. Everolimus, an …

Background & Aims Sorafenib is the only therapy shown to improve overall survival in
advanced hepatocellular carcinoma (HCC). Combination therapy targeting multiple …

e14542 Background: The PI3K/Akt/mTOR pathway plays a critical role in HCC
pathogenesis. We performed a phase I/II study of everolimus (RAD001), an oral inhibitor of …

Abstract BACKGROUND: The phosphoinositide 3‐kinase/Akt/mammalian target of
rapamycin pathway plays a critical role in the pathogenesis of hepatocellular carcinoma …

Importance Aside from the multikinase inhibitor sorafenib, there are no effective systemic
therapies for the treatment of advanced hepatocellular carcinoma. Objective To assess the …

TPS213 Background: The multikinase inhibitor SOR prolongs survival in patients with
advanced HCC. Another pathway often active in HCC is mammalian target of rapamycin …

e14567 Background: The mTOR pathway has a central role in HCC not only in the tumor
growth but also in the insulin driven hepatocarcinogenesis and is reported activated in 40 …

Background Sorafenib (S), a multitargeted tyrosine kinase inhibitor, is the standard of care
for first-line systemic treatment of advanced hepatocellular carcinoma (HCC). Everolimus (E) …

Background Based upon preclinical evidence for improved antitumor activity in combination,
this phase I study investigated the maximum-tolerated dose (MTD), safety, activity …

Background The combination of bevacizumab (B) and erlotinib (E) has shown promising
clinical outcomes as the first-line treatment of advanced HCC patients. We aimed to evaluate …